Neuron-glia interactions as therapeutic targets in neurodegeneration

Journal of Alzheimer's Disease

Volumn 16, Issue 3, 2009, Pages 485-502

  Salmina, Alla B ^a  

^a KRASNOYARSK STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Alzheimer disease; Glia mediated response; Neuron glia interactions; Neurovascular unit

Indexed keywords

AMYLOID BETA PROTEIN; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE; TAU PROTEIN;

ALZHEIMER DISEASE; ASTROCYTE; CELL COMMUNICATION; CELL ENERGY; CELL FUNCTION; CELL INTERACTION; CELL REGENERATION; ENERGY METABOLISM; GLUCOSE METABOLISM; GLYCOLYSIS; HOMEOSTASIS; HUMAN; MICROGLIA; NERVE CELL LESION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEOMICS; REVIEW; STEROIDOGENESIS; SYNAPSE; ANIMAL; GLIA; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; CELL COMMUNICATION; HUMANS; NERVE DEGENERATION; NEUROGLIA; NEURONS;

EID: 65549149134     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-0988     Document Type: Review

References (178)

1. Selkoe DJ (2005) Defining molecular targets to prevent Alzheimer disease. Arch Neurol 62, 192-195.
2. Abramov AY, Canevari L, Duchen MR (2004) β-Amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 24, 565-575.
3. Russo C, V.Venezia, E.Repetto, M.Nizzari, E.Violani, P.Carlo and G.Schettini (2005) The amyloid precursor protein and its network of interacting proteins: physiological and pathological implications. Brain Res Rev 48, 257-264.
4. Terry RD (2006) Alzheimer's disease and the aging brain. J Geriatr Phychiatry Neurol 2006, 125-128.
5. Jacobsen JS, Wu C-C, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 103, 5161-5166.
6. Montine TJ, Morrow JD (2005) Fatty acid oxidation in the pathogenesis of Alzheimer's disease. Am J Pathol 166, 1283-1289.
7. Burke SN, Barnes CA (2006) Neuroal plasticity in the ageing brain. Nature Rev Neurosci 7, 30-40.
8. Mattson MP, Magnus T (2006) Ageing and neuronal vulnerability. Nature Rev Neurosci 7, 278-294.
9. Ziabreva I, Perry E, Perry R, Minger SL, A. E, Przyborski S, Ballard C (2006) Altered neurogenesis in Alzheimer's disease. J Psychosomatic Res 61, 311-316.
10. Castellani RJ, Zhu X, Lee H-G, Perry G, Smith MA, Casadesus G (2006-07) Neurogenesis in human hippocampus: implications for Alzheimer disease pathogenesis. Neuroembryol Aging 4, 175-182.
11. Bertram L, Tanzi RE (2004) Alzheimer's disease: one disorder, too many genes? Hum Mol Genet 13, R135-141.
12. Bullock R (2002) New drugs for Alzheimer's disease and other dementias. Br J Psychiatry 180, 135-139.
13. Ho L, Sharma N, Blackman L, Festa E, Reddy G, Pasinetti GM (2005) From proteomics to biomarker discovery in Alzheimer's disease. Brain Res Rev 48, 360-369.
14. Klafki H-W, Staufenbiel M, Kornhuber J, Wiltfang J (2006) Therapeutic approaches to Alzheimer's disease. Brain 129, 2840-2855.
15. Dabir DV, Robinson MB, Swanson E, Zhang B, Trojanows-ki JQ, Lee VMY, Forman MS (2006) Impaired glutamate transport in a mouse model of tau pathology in astrocytes. J. Neurosci. 26, 644-654.
16. Mrak RE, Griffin WST (2005) Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 26, 349-354.
17. Nagele RG, Wegiel J (2004) Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 25, 663-674.
18. Seifert G, Schilling K, Steinhauser C (2006) Astrocyte dysfunction in neurological disorders: a molecular perspective. Nature Rev Neurosci 7, 194-206.
19. Alarcon R, Fuenzalida C, Santibanez M, von Bernhardi R (2005) Expression of scavenger receptors in glial cells: comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound β-amyloid. J Biol Chem 280, 30406-30415.
20. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, Romero J (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neu-ritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23, 11136-11141.
21. Mouser PE, Head E, Ha K-H, Rohn TT (2006) Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain. Am J Pathol 168, 936-946.
22. Yin K-J, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X, Bate-man R, Song H, Hsu F-F, Turk J, Xu J, Hsu CY, Mills JC, Holtzman DM, Lee J-M (2006) Matrix metalloproteinases expressedbyastrocytes mediate extracellularamyloid-β pep-tide catabolism. J Neurosci 26, 10939-10948.
23. Butterfield DA, Boyd-Kimball D, Castegna A (2003) Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J Neurochem 86, 1313-1327.
24. Itoh Y, Esaki T, Shimoji K, Cook M, Law MJ, Kaufman E, Sokoloff L (2003) Dichloroacetate effects on glucose and lactate oxidation by neurons and astroglia in vitro and on glucose utilization by brain in vivo. Proc Natl Acad Sci U S A 100, 4879-4884.
25. Benarroch EE (2005) Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. Mayo Clin Proc 80, 1326-1338.
26. Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong C-X (2008) Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 582, 359-364.
27. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP (1997) Amyloid β-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci 17, 1046-1054.
28. Pellerin L, Pellegri G, Bittar PG, Charnay Y, Bouras C, Martin JL, Stella N, Magistretti PJ (1998) Evidence supporting the existence of an activity-dependent astrocyte-neuron lac-tate shuttle. Dev Neurosci 20, 291-299.
29. Magistretti PJ (2000) Cellular bases of functional brain imaging: insights from neuron-glia metabolic coupling. Brain Res Rev 886, 108-112.
30. Robinson SR (2000) Neuronal expression of glutamine syn-thetase in Alzheimer's disease indicates a profound impairment of metabolic interactions with astrocytes. Neurochem Int 36, 471-482.
31. Atamna H, Frey Ii WH (2007) Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion 7, 297-310.
32. HoyerS(1993) Abnormalitiesinbrain glucoseutilization and its impact on cellular and molecular mechanisms in sporadic dementia of Alzheimer type. Ann N Y Acad Sci 695, 77-80.
33. Hirono N, Mori E, Ishii K, Kitagaki H, Sasaki M, Ikejiri Y, Imamura T, Shimomura T, Ikeda M, Yamashita H (1998) Alteration of regional cerebral glucose utilization with delusions in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 10, 433-439.
34. Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, Matsuda K, Mori E (1997) Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J Nucl Med 38, 925-928.
35. Hirono N, Hashimoto M, Ishii K, Kazui H, Mori E (2004) One-year change in cerebral glucose metabolism in patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 16, 488-492.
36. Schubert D (2005) Glucose metabolism and Alzheimer's disease. Ageing Res Rev 4, 240-257.
37. Loessner A, Alavi A, Lewandrowski KU, Mozley D, Souder E, Gur RE (1995) Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J Nucl Med 36, 1141-1149.
38. Sorra KE, Harris KM (2000) Overview on the structure, composition, function, development, and plasticity of hippocam-pal dendritic spines. Hippocampus 10, 501-511.
39. Chih C-P, Roberts Jr EL(2003) Energy substrates for neurons during neural activity: a critical review of the astrocyte-neuron lactate shuttle hypothesis.J Cerebr Blood FlowMetab 23, 1263-1281.
40. Shim KS, Lubec G (2002) Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci Lett 324, 209-212.
41. Anandatheerthavarada HK, Biswas G, Robin M-A, Avadhani NG (2003) Mitochondrial targeting and a novel transmem-brane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161, 41-54.
42. Arias C, Montiel T, Quiroz-Baez R, Massieu L (2002) β-amyloid neurotoxicity is exacerbated during glycolysis inhibition and mitochondrial impairment in the rat hippocampus in vivo and in isolated nerve terminals: implications for Alzheimer's disease. Exp Neurol 176, 163-174.
43. Parihar MS, Brewer GJ (2007) Mitoenergetic failure in Alzheimer disease. Am J Physiol Cell Physiol 292, C8-23.
44. Coskun PE, Beal MF, Wallace DC (2004) Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci 101, 10726-10731.
45. Manczak M, Park B, Jung Y, Reddy P (2004) Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease. NeuroMolecular Med 5, 147-162.
46. Wang X, Su B, Perry G, Smith MA, Zhu X (2007) Insights into amyloid-β-induced mitochondrial dysfunction in Alzheimer disease. Free Radic Biol Med 43, 1569-1573.
47. Lin MT, Simon DK, Ahn CH, Kim LM, Beal MF (2002) High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum Mol Genet 11, 133-145.
48. Gibson GE, Sheu KFR, Blass JP (1998) Abnormalities of mi-tochondrial enzymes in Alzheimer disease. J Neural Transm 105, 855-870.
49. Almeida A,Almeida J,Bolanos JP, Moncada S (2001) Different responses of astrocytes and neurons to nitric oxide: The role of glycolytically generated ATP in astrocyte protection. Proc Natl Acad Sci U S A 98, 15294-15299.
50. Boldyrev AA, JohnsonP(2007) Homocysteine and its derivatives as possible modulators of neuronal and non-neuronal cell glutamate receptors in Alzheimer's disease. J Alzheimers Dis 11, 219-228.
51. Enokido Y, Suzuki E, Iwasawa K, Namekata K, Okazawa H, Kimura H (2005) Cystathionine b-synthase, a key enzyme for homocysteine metabolism, is preferentially expressed in the radial glia/astrocyte lineage of developing mouse CNS. FASEB J 19, 1854-1856.
52. Jin Y, Brennan L (2008) Effects of homocysteine on metabolic pathways in cultured astrocytes. Neurochem Int 52, 1410-1415.
53. Brewer GJ, Wallimann TW (2000) Protective effect of the energy precursor creatine against toxicity of glutamate and β-amyloid in rat hippocampal neurons. J Neurochem 74, 1968-1978.
54. Massieu L,Del Rio P, Montiel T(2001) Neurotoxicity of glutamate uptake inhibition in vivo: correlation with succinate dehydrogenase activity and prevention by energy substrates. Neuroscience 106, 669-677.
55. Ying W, Chen Y, Alano CC, Swanson RA (2002) Tricar-boxylic acid cycle substrates prevent PARP-mediated death of neurons and astrocytes. J Cereb Blood Flow Metab 22, 774-779.
56. Magni G, Amici A, Emanuelli M, Orsomando G, Raffaelli N, Ruggieri S (2004) Enzymology of NAD+ homeostasis in man. Cell Mol Life Sci 61, 19-34.
57. Suh HS, Zhao ML, Rivieccio M, Choi S, Connoly E, Zhao Y, Takikawa O, Brosnan CF, Lee H-G (2007) Astrocyte in-doleamine 2,3-dioxygenase is induced by the TLR3 ligand poly(I:C): mechanism of induction and role in antiviral response. J Virol 81, 9838-9850.
58. Ying W (2006) NAD+ and NADH in cellular functions and cell death. Front Biosci 11, 3129-3148.
59. Dong-Ruyl L, Sawada M, Nakano K (1998) Tryptophan and its metabolite, kynurenine, stimulate expression of nerve growth factor in cultured mouse astroglial cells. Neurosci Lett 244, 17-20.
60. Oxenkrug GF (2007) Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging. Ann NY Acad Sci 1122, 35-49.
61. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM (2005) Indoleamine 2,3-dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropath Appl Neurobiol 31, 395-404.
62. Fukuoka S-I, Ishiguro K, Yanagihara K, Tanabe A, Egashira Y, Sanada H, Shibata K (2002) Identification and expression of a cDNA encoding human a-amino-b-carboxymuconate-e-semialdehyde decarboxylase (ACMSD). J Biol Chem 277, 35162-35167.
63. Guillemin GJ, Kerr SJ, Smythe GA, Smith MA, Kapoor V, Armati PJ, Croitoru J, Brew BJ (2001) Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 78, 842-853.
64. Raffaelli N, Sorci L, Amici A, Emanuelli M, Mazzola F, MagniG (2002) Identificationof a novel human nicotinamide mononucleotide adenylyltransferase. Biochem Biophys Res Commun 297, 835-840.
65. Liu F, Arias-Vasquez A, Sleegers K, Aulchenko YS, Kayser M, Sanchez-JuanP,Feng B-J, Bertoli-AvellaAM, SwietenJv, Axenovich TI, Heutink P, Broeckhoven Cv, Oostra BA, Duijn CMv (2007) A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. Am J Hum Genet 81, 17-31.
66. Zhai RG, Zhang F, Hiesinger PR, Cao Y, Haueter CM, Bellen HJ (2008) NAD synthase NMNAT acts as a chaperone to protect against neurodegeneration. Nature 452, 887-891.
67. Di Lisa F, Ziegler M (2001) Pathophysiological relevance of mitochondria in NAD+ metabolism. FEBS Letters 492, 4-8.
68. Grant RS, Kapoor V (1998) Murine glial cells regenerate nad, after peroxide-induced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. J Neurochem 70, 1759-1763.
69. Kauppinen TM, Swanson RA (2007) The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience 145, 1267-1272.
70. Ziegler M (2000) New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur J Biochem 267, 1550-1564.
71. Oliver FJ, Menissier-de Murcia J, de Murcia G (1999) Poly(ADP-ribose) polymerase in the cellular response to DNA damage, apoptosis, and disease. Am J Hum Genet 64, 1282-1288.
72. Alano CC, Ying W, Swanson RA (2004) Poly(ADP-ribose) Polymerase-1- mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition. J Biol Chem 279, 18895-18902.
73. Love S, Barber R, Wilcock GK (1999) Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease. Brain 122, 247-253.
74. Du L, Zhang X, Han YY, Burke NA, Kochanek PM, Watkins SC, Graham SH, Carcillo JA, Szabo C, Clark RSB (2003) Intra-mitochondrial Poly(ADP- ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem 278, 18426-18433.
75. Adamczyk A, Jesko H, Strosznajder RP (2005) Alzheimer's disease related peptides affected cholinergic receptor mediated poly(ADP-ribose) polymerase activity in the hippocampus. Folia Neuropathologica 43, 139-142.
76. Pieper AA, Blackshaw S, Clements EE, Brat DJ, Krug DK, White AJ, Pinto-Garcia P, Favit A, Conover JR, Snyder SH, Verma A (2000) Poly(ADP-ribosyl)ation basally activated by DNA strand breaks reflects glutamate-nitric oxide neuro-transmission. Proc Natl Acad Sci U S A 97, 1845-1850.
77. Cerdan S, Rodrigues TB, Sierra A, Benito M, Fonse-ca LL, Fonseca CP, García-Martín ML (2006) The redox switch/redox coupling hypothesis. Neurochem Int 48, 523-530.
78. Deaglio S, Aydin S, Vaisitti T, Bergui L, Malavasi F (2008) CD38 at the junction between prognostic marker and therapeutic target. Trends Mol Med 14, 210-218.
79. Higashida H, Hashii M, Yokoyama S, Hoshi N, Chen X-L, Egorova A, Noda M, Zhang J-S (2001) Cyclic ADP-ribose as a second messenger revisited from a new aspect of signal transduction from receptors to ADP-ribosyl cyclase. Pharmacol Ther 90, 283-296.
80. Higashida H, Salmina AB, Olovyannikova RY, Hashii M, Yokoyama S, Koizumi K, Jin D,Liu H-X, Lopatina O, Amina S, Islam MS, Huang J-J, Noda M (2007) Cyclic ADP-ribose as a universal calcium signal molecule in the nervous system. Neurochem Int 51, 192-199.
81. Salmina AB, Olovyannikova RY, Noda M, Higashida H (2006) ADP-ribosyl cyclase as a therapeutic target for central nervous system diseases. Curr Medic Chem 6, 193-210.
82. Ceni C, Pochon N, Brun V, Muller-Steffner Hl, Andrieux A, Grunwald D, Schuber F, De Waard M, Lund F, Villaz M, Moutin M-J (2003) CD38-dependent ADP-ribosyl cyclase activity in developing and adult mouse brain. Biochem J 370, 175-183.
83. MizuguchiM,OtsukaN,SatoM,IshiiY,Kon S-i, Yamada M, Nishina H, Katada T, Ikeda K (1995) Neuronal localization of CD38 antigen in the human brain. Brain Res 697, 235-240.
84. Hotta T, Asai K, Fujita K, Kato T, Higashida H (2000) Membrane-bound form of ADP-ribosyl cyclase in rat cortical astrocytes in culture. J Neurochem 74, 669-675.
85. Bruzzone S, Verderio C, Schenk U, Fedele E, Zocchi E, Matteoli M, De Flora A (2004) Glutamate-mediated over-expression of CD38 in astrocytes cultured with neurones. J Neurochem 89, 264-272.
86. Otsuka K, Mizuguchi M, Aizawa T, Haga S, Sato M, Inoya H, Namba Y, Hofbauer J, Marberger M (1994) Immunoreac-tivity in Alzheimer's neurofibrillary tangles. Brain Pathol 4, 558.
87. Ying W, Alano CC, Garnier P, Swanson RA (2005) NAD+ as a metabolic link netween DNA damage and cell death. J Neurosci Res 79, 216-223.
88. Norris CM, Kadish I, Blalock EM, Chen K-C, Thibault V, Porter NM, Landfield PW, Kraner SD (2005) Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models. J Neurosci 25, 4649-4658.
89. Matyash M, Matyash V, Nolte C, Sorrentino V, Kettenmann H (2002) Requirement of functional ryanodine receptor type 3 for astrocyte migration. FASEB J 16, 84-86.
90. Heidemann AC, Schipke CG, Kettenmann H (2005) Extracellular application of nicotinic acid adenine dinucleotide phosphate induces Ca2+ signaling in astrocytes in situ. J Biol Chem 280, 35630-35640.
91. Pawlikowska L, Votrell SE, Harms MB, Li Y, Rosenberg PA (1996) Extracellular synthesis of cADP-ribose from nicotinamide-adenine dinucleotide by rat cortical astrocytes in culture. J Neurosci 16, 5372-5381.
92. Kelliher M, Fastbom J, Cowburn RF, Bonkale W, Ohm TG, Ravid R, Sorrentino V, O'Neill C (1999) Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and β-amyloid pathologies. Neuroscience 92, 499-513.
93. Supnet C, Grant J, Kong H, Westaway D, Mayne M (2006) Amyloid-β-(1-42) increases ryanodinereceptor-3 expression and function in neurons of TgCRND8 mice. J Biol Chem 281, 38440-38447.
94. Bezprozvanny I, Mattson MP (2008) Neuronal calcium mishandling and the pathogenesisof Alzheimer's disease. Trends Neurosci 31, 454-463.
95. Braidy N, Guillemin G, Grant R (2008) Promotion of cellular NAD(+) anabolism: therapeutic potential for oxidative stress in ageing and Alzheimer's disease. Neurotox Res 13, 173-184.
96. + metabolism. J Alzheimers Dis 6, S43-S46.
97. Anekonda TS, Reddy PH (2006) Neuronal protection by sir-tuins in Alzheimer's disease. J Neurochem 96, 305-313.
98. Khan JA, Forouhar F, Tao X, Tong L (2007) Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets 11, 695-705.
99. Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, Zhao W, Thiyagarajan M, MacGrogan D, Rodgers JT, Puigserver P, Sadoshima J, Deng H, Pedrini S, Gandy S, Sauve AA, Pasinetti GM (2006) Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 281, 21745-21754.
100. Demarin V, Podobnik SS, Storga-Tomic D, Kay G (2004) Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. Drugs Exp Clin Res 30, 27-33.
101. Zhu K, Swanson RA, Ying WC (2005) NADH can enter into astrocytes and block poly(ADP-ribose) polymerase-1-mediated astrocyte death. Neuroreport 16, 1209-1212.
102. Rainer M, Kraxberger E, Haushofer M, Mucke HAM, Jellinger KA (2000) No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia. J Neural Transm 107, 1475-1481.
103. Chini EN, Barbosa MTP, Soares SM (2007) CD38 as a target for obesity, metabolic syndrome related disorders, and dementia (including Alzheimer's disease). www.mayoclinictechnology.com/tc/therapeutics/2007-2187-1462.html.
104. Verderio C, Bruzzone S, Zocchi E,Fedele E,Schenk U, Flora AD, Matteoli M (2001) Evidence of a role for cyclic ADP-ribose in calcium signalling and neurotransmitter release in cultured astrocytes. J Neurochem 78, 646-657.
105. Lu H, Burns D, Garnier P, Wei G, Zhu K, Ying W (2007) P2X7 receptors mediate NADH transport across the plasma membranes of astrocytes. Biochem Biophys Res Commun 362, 946-950.
106. Maragakis NJ, Rothstein JD (2001) Glutamate transporters in neurologic disease. Arch Neurol 58, 365-370.
107. Ly CV, Verstreken P (2006) Mitochondria at the synapse. Neuroscientist 12, 291-299.
108. Innocenti B, Parpura V, Haydon PG (2000) Imaging extracellular waves of glutamate during calcium signaling in cultured astrocytes. J Neurosci 20, 1800-1808.
109. Rossi D, Brambilla L, Valori CF, Crugnola A, Giaccone G, Capobianco R, Mangieri M, Kingston AE, Bloc A, Bezzi P, Volterra A (2005) Defective tumor necrosis factor-a-dependent control of astrocyte glutamate release in a trans-genic mouse model of Alzheimer disease. J Biol Chem 280, 42088-42096.
110. Santello M, Volterra A (2009) Synaptic modulation by astro-cytes via Ca2+-dependent glutamate release. Neuroscience 158, 253-259.
111. Ye Z-C, Wyeth MS, Baltan-Tekkok S, Ransom BR (2003) Functional hemichannels in astrocytes: a novel mechanism of glutamate release. J Neurosci 23, 3588-3596.
112. Nagy JI, Dudek FE, Rash JE (2004) Update on connexins and gap junctions in neurons and glia in the mammalian nervous system. Brain Res Rev 47, 191-215.
113. Nakase T, Naus CC (2004) Gap junctions and neurological disorders of the central nervous system. Biochim Biophys Acta 1662, 149-158.
114. Contreras JE, Sanchez HA, Veliz LP, Bukauskas FF, Bennett MVL, Saez JC (2004) Role of connexin-based gap junction channels and hemichannels in ischemia-induced cell death in nervous tissue. Brain Res Rev 47, 290-303.
115. Nagy JI, Li W, Hertzberg EL, Marotta CA (1996) Elevated connexin43 immunoreactivity at sites of amyloid plaques in alzheimer's disease. Brain Res 717, 173-178.
116. Bolanos JP, Medina JM (1996) Induction of nitric oxide synthase inhibits gap junction permeability in cultured rat astrocytes. J Neurochem 66, 2091-2099.
117. Butkevich E, Hülsmann S, Wenzel D, Shirao T, Duden R, Majoul I (2004) Drebrin is a novel connexin-43 binding partner that links gap junctions to the submembranecytoskeleton. Current Biology 14, 650-658.
118. Hallaq RY, Killick R (2006) P1-415: Connexin-43: A potential transduction target for amyloid intracellular domain? Alzheimers Dement 2, S219-S219.
119. Kielian T (2008) Glial connexins and gap junctions in CNS inflammation and disease. J Neurochem 106, 1000-1016.
120. Franco L, Zocchi E, Usai C, Guida L, Bruzzone S, Costa A, De Flora AG (2001) Paracrine roles of NAD+ and cyclic ADP-ribose in increasing intracellular calcium and enhancing cell proliferation of 3T3 fibroblasts. J Biol Chem 276, 21642-21648.
121. Filosa JA, Bonev AD, Nelson MT (2004) Calcium dynamics in cortical astrocytes and arterioles during neurovascular coupling. Circ Res 95, e73-81.
122. Girouard H, Iadecola C (2006) Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol 100, 328-335.
123. de la Torre JC (2002) Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33, 1152-1162.
124. Hsu M-J, Hsu CY, Chen B-C, Chen M-C, Ou G, Lin C-H (2007) Apoptosis signal-regulating kinase 1 in amyloid β-peptide-induced cerebral endothelial cell apoptosis. J Neurosci 27, 5719-5729.
125. Lo EH (2006) Neurovascular mechanisms in stroke, neu-rodegeneration and recovery. Korean J Physiol Pharmacol 10, 223-229.
126. Miao J, Xu F, Davis J, Otte-Holler I, Verbeek MM, Van Nos-trand WE (2005) Cerebral microvascular amyloid β-protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid β precursor protein. Am J Pathol 167, 505-515.
127. Minghetti L, Ajmone-Cat MA, De Berardinis MA, De Si-mone R (2005) Microglial activation in chronic neurode-generative diseases: roles of apoptotic neurons and chronic stimulation. Brain Res Rev 48, 251-256.
128. Cullheim S, Thams S (2007) The microglial networks of the brain and their role in neuronal network plasticity after lesion. Brain Res Rev 55, 89-96.
129. Owens T, Babcock AA, Millward JM, Toft-Hansen H (2005) Cytokine and chemokine inter-regulation in the inflamed or injured CNS. Brain Res Rev 48, 178-184.
130. Wilkinson BL, Landreth GE (2006) The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflam 3, 30.
131. Parvathenani LK, Tertyshnikova S, Greco CR, Roberts SB, Robertson B,Posmantur R(2003) P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem 278, 13309-13317.
132. Farber K, Kettenmann H (2005) Physiology of microglial cells. Brain Res Rev 48, 133-143.
133. Shimohama S,TaninoH,Kawakami N,Okamura N,Kodama H, Yamaguchi T, Hayakawa T, Nunomura A, Chiba S, Perry G, Smith MA, Fujimoto S (2000) Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun 273, 5-9.
134. Serrano F, Kolluri NS, Wientjes FB, Card JP, Klann E (2003) NADPH oxidase immunoreactivity in the mouse brain. Brain Res 988, 193-198.
135. Noh K-M, Koh J-Y (2000) Induction and activationby zinc of NADPH oxidase in cultured cortical neurons and astrocytes. J Neurosci 20, 111RC-.
136. Park L, Anrather J, Zhou P, Frys K, Pitstick R, Younkin S, Carlson GA, Iadecola C (2005) NADPH oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid β peptide. J Neurosci 25, 1769-1777.
137. Tong X-K, Nicolakakis N, Kocharyan A, Hamel E (2005) Vascular remodeling versus amyloid β-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J Neurosci 25, 11165-11174.
138. Miller AA, Drummond GR, Sobey CG (2006) Novel isoforms of NADPH-oxidase in cerebral vascular control. Pharmacol Ther 111, 928-948.
139. Kielian T, Esen N (2004) Effects of neuroinflammation on glia-glia gap junctional intercellular communication: a perspective. Neurochem Int 45, 429-436.
140. Meme W, Calvo C-F, Froger N,Ezan P, Amigou E, Koulakoff A, Giaume C (2006) Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: potentia-tion by β-amyloid. FASEB J 20, 494-496.
141. Yokoyama A, Yang L, Itoh S, Mori K, Tanaka J (2004) Mi-croglia, a potential source of neurons, astrocytes, and oligo-dendrocytes. Glia 45, 96-104.
142. Streit WJ (2005) Microglia and neuroprotection: implications for Alzheimer's disease. Brain Res Rev 48, 234-239.
143. Papadopoulos V, Lecanu L, Brown RC, Han Z, Yao ZX (2006) Peripheral-type benzodiazepine receptor in neuros-teroid biosynthesis, neuropathology and neurological disorders. Neuroscience 138, 749-756.
144. Garcia-Ovejero D, Azcoitia I, DonCarlos LL, Melcangi RC, Garcia-Segura LM (2005) Glia-neuron crosstalk in the neu-roprotective mechanisms of sex steroid hormones. Brain Res Rev 48, 273-286.
145. Nichols NR (1999) Glial responses to steroids as markers of brain aging. J Neurobiol 40, 585-601.
146. Yue X, Lu M, Lancaster T, Cao P, Honda S-I, Staufenbiel M, Harada N, Zhong Z, Shen Y, Li R (2005) Brain estrogen deficiency accelerates Aβ plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci U S A 102, 19198-19203.
147. Bartzokis G, Lu PH, Mintz J (2007) Human brain myeli-nation and amyloid beta deposition in Alzheimer's disease. Alzheimers Dement 3, 122-125.
148. Lee J-T, Xu J, Lee J-M, Ku G, Han X, Yang D-I, Chen S, Hsu CY (2004) Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol 164, 123-131.
149. Roth AD, RamirezG,Alarcon R, Bernhardi Rv(2005) Oligo-dendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. Biol Res 38, 381-387.
150. Liu X, Liu Y-Y, Jin W-L, Liu H-L, Ju G (2005) Nogo-66 receptor at cerebellar cortical glia gap junctions in the rat. Neurosignals 14, 96-101.
151. Park JH, Gimbel DA, GrandPre T, Lee J-K, Kim J-E, Li W, Lee DHS, Strittmatter SM (2006) Alzheimer precursor protein interaction with the nogo-66 receptor reduces amyloid-β plaque deposition. J Neurosci 26, 1386-1395.
152. von Bernhardi R (2007) Glial cell dysregulation: a new perspective on Alzheimer disease. Neurotox Res 12, 215-232.
153. Takuma K, Baba A, Matsuda T (2004) Astrocyte apoptosis: implications for neuroprotection. Prog Neurobiol 72, 111-127.
154. Shah RS, Lee H-G, Xiongwei Z, Perry G, Smith MA, Castellani RJ (2008) Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother 62, 199-207.
155. Hagen TM, Liu J, Lykkesfeldt J, Wehr CM, Ingersoll RT, Vinarsky V, Bartholomew JC, Ames BN (2002) Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci U S A 99, 1870-1875.
156. Mannerström M, Tähti H (2004) Modulation of glucose uptake in glial and neuronal cell lines by selected neurological drugs. Toxicol Lett 151, 87-97.
157. Quinn JF, Bussiere JR, Hammond RS, Montine TJ, Henson E, Jones RE, Stackman JRW (2007) Chronic dietary a-lipoic acid reduces deficitsin hippocampal memory ofaged Tg2576 mice. Neurobiol Aging 28, 213-225.
158. Iliff JJ, Close LN, Selden NR, Alkayed NJ (2007) A novel role for P450 eicosanoids in the neurogenic control of cerebral blood flow in the rat. Exp Physiol 92, 653-658.
159. Heneka MT, O'Banion MK (2007) Inflammatory processes in Alzheimer's disease. J Neuroimmunol 184, 69-91.
160. Ranaivo HR, Craft JM, Hu W, Guo L, Wing LK, Van Eldik LJ, Watterson DM (2006) Glia as a therapeutic target: selective suppression of human amyloid-β-induced upregula-tion of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 26, 662-670.
161. Xu J, Chavis JA, Racke MK, Drew PD (2006) Peroxisome proliferator- activated receptor-a and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 176, 95-105.
162. Xu J, Drew PD (2006) 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J Neuroimmunol 171, 135-144.
163. Chen J, Zhou Y, Mueller-Steiner S, Chen L-F, Kwon H, Yi S, Mucke L, Gan L (2005) SIRT1 Protects against microglia-dependent amyloid-β toxicity through inhibiting NF-κB signaling. J Biol Chem 280, 40364-40374.
164. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE (2005) Acute treatment with the PPAR-γ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453.
165. Outeiro TF, Marques O, Kazantsev A (2008) Therapeutic role of sirtuins in neurodegenerative disease. Biochim Biophys Acta 1782, 363-369.
166. Brinton RD (2001) Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease: recent insights and remaining challenges. Learn Mem 8, 121-133.
167. Park JH, Widi GA, Gimbel DA, Harel NY, Lee DHS, Strittmatter SM (2006) Subcutaneous nogo receptor removes brain amyloid-β and improves spatial memory in Alzheimer's transgenic mice. J Neurosci 26, 13279-13286.
168. Pereira C, Santos MS, Oliveira C (1999) Involvement of oxidative stress on the impairment of energy metabolism induced by Aβ peptides on PC12 cells: protection by antioxidants. Neurobiol Dis 6, 209-219.
169. Jin Y, Brennan L (2008) Effects of homocysteine on metabolic pathways in cultured astrocytes. Neurochem Int 52, 1410-1415.
170. Vincent B, Smith J (2001) Astrocytes down-regulate neuronal b-amyloid precursor protein expression and modify its processing in an apolipoprotein E isoform-specific manner. Eur J Neurosci 14, 256-266.
171. Mentlein R, Ludwig R, Martensen I (1998) Proteolytic degradation of Alzheimer's disease amyloid β-peptide by a metal-loproteinase from microglia cells. J Neurochem 70, 721-726.
172. Hauwel M, Furon E, Canova C, Griffiths M, Neal J, Gasque P (2005) Innate (inherent) control of brain infection, brain inflammation and brain repair: the role of microglia, astrocytes, "protective" glial stem cells and stromal ependymal cells. Brain Res Rev 48, 220-233.
173. Vesce S, Rossi D, Brambilla L, Volterra A, Giacinto Bagetta MTC, Stuart AL (2007) Glutamate release from astrocytes in physiological conditions and in neurodegenerative disorders characterized by neuroinflammation. Int Rev Neurobiol 82, 57-71.
174. Streit WJ, Conde JR, Harrison JK (2001) Chemokines and Alzheimer's disease. Neurobiol Aging 22, 909-913.
175. Giulian D (1999) Microglia and the immune pathology of Alzheimer disease. Am J Hum Genet 65, 13-18.
176. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW (1993) Cytotoxicity of microglia. Glia 7, 111-118.
177. Marx CE, Trost WT, Shampine LJ, Stevens RD, Hulette CM, Steffens DC, Ervin JF, Butterfield MI, Blazer DG, Massing MW, Lieberman JA (2006) The neurosteroid allopreg-nanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol Psychiatry 60, 1287-1294.
178. Seri B, Garcia-Verdugo JM, McEwen BS, Alvarez-Buylla A (2001) Astrocytes give rise to new neurons in the adult mammalian hippocampus. J Neurosci 21, 7153-7160.